Clinical Trial Update: Biochemical Correction of Severe EB by Allo HSCT and "Off-the-shelf" MSCs [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial investigated biochemical correction of severe Epidermolysis Bullosa using allogeneic hematopoietic stem cell transplantation and off-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epidermolysis Bullosa

Drugs mentioned

• Allogeneic hematopoietic stem cells (hematopoietic stem cell transplantation)
• Off-the-shelf mesenchymal stem cells (mesenchymal stem cells)

Snippet

Sponsor: Masonic Cancer Center, University of Minnesota | Conditions: Epidermolysis Bullosa | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-04-03